EMT signaling: potential contribution of CRISPR/Cas gene editing.
CRISPR
Cancer
Epithelial–mesenchymal transition
Gene editing
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
03
06
2019
accepted:
02
01
2020
revised:
24
12
2019
pubmed:
3
2
2020
medline:
11
7
2020
entrez:
3
2
2020
Statut:
ppublish
Résumé
Epithelial to mesenchymal transition (EMT) is a complex plastic and reversible cellular process that has critical roles in diverse physiological and pathological phenomena. EMT is involved in embryonic development, organogenesis and tissue repair, as well as in fibrosis, cancer metastasis and drug resistance. In recent years, the ability to edit the genome using the clustered regularly interspaced palindromic repeats (CRISPR) and associated protein (Cas) system has greatly contributed to identify or validate critical genes in pathway signaling. This review delineates the complex EMT networks and discusses recent studies that have used CRISPR/Cas technology to further advance our understanding of the EMT process.
Identifiants
pubmed: 32008085
doi: 10.1007/s00018-020-03449-3
pii: 10.1007/s00018-020-03449-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM